Abstract: Objective The aim of this study was to explore the efficacy of lauromacrogol and anhydrous ethanol sclerotherapy under ultrasound guidance in the treatment of patients with hepatic cysts (HC). Methods 107 patients with HC were enrolled in our hospital between October 2019 and October 2022, and were divided randomly into observation (n=54) and control group (n=53), receiving lauromacrogol or absolute ethanol sclerotherapy under ultrasound (US) guidance. After 6 months of treatment, the ultrasonography was performed, and the clinical efficacy was evaluated. Serum Golgi protein 73 (GP73), protein disulfide isomerase A3 (PDIA3) and chitosanase 3-like protein 1 (CHI3L1) levels were detected by fluoroimmunoassay. Serum myeloperoxidase (MPO) and cortisol (Cor) levels were measured by ELISA, and serum amyloid A (SAA) level was detected by chemiluminescence. The visual analogue scale (VAS) score was evaluated. Results The total effectiveness rate in the observation group was 98.1%, significantly higher than 88.7% in the control group (P<0.05), and at the end of six-month of follow-up, the recurrence of HC was 3.7%, much lower than 16.9%(P<0.05) in the control; one week after operation, serum GP73, PDIA3 and CHI3L1 levels in the observation group were (23.1±3.8)pg/L, (69.2±5.6)ng/mL and (44.9±4.9)ng/L, all significantly lower than [(37.3±4.3)pg/L, (94.8±5.4)ng/mL and (67.7±4.6)ng/L, respectively, P<0.05] in the control; serum MPO, Cor and SAA levels were (121.5±18.3)U/L, (259.7±24.1)ng/L and (14.5±2.5)mg/L, all significantly lower [(158.1±20.1)U/L, (298.6±26.3)ng/L and (20.2±3.1)mg/L, respectively, P<0.05] in the control; at day one and three after sclerotherapy, the VAS score in the observation group were (3.1±0.6) and (2.2±0.3), both much less than [(4.5±0.5) and (3.2±0.4), P<0.05] in the control; the incidence of untoward effect, such as abdominal pain and drunkenness-like symptoms in the observation group was 3.7%, much lower than 20.8%(P<0.05) in the control group. Conclusion The sclerotherapy with lauromacrogol injection in the treatment of patients with HC has a relatively better clinical efficacy as compared to the ethanol injection, which might be related to a low body stress reaction and low incidence of side effects.

Key words: Hepatic cysts, Lauromacrogol, Anhydrous ethanol, Ultrasound-guidance, Sclerotherapy, Therapy